Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism

被引:91
|
作者
Uto, K
Inoue, D
Shimuta, K
Nakajo, N
Sagata, N
机构
[1] Kyushu Univ, Dept Biol, Grad Sch Sci, Fukuoka 8128581, Japan
[2] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan
来源
EMBO JOURNAL | 2004年 / 23卷 / 16期
关键词
Cdc25; cell cycle checkpoint; Chk1; Chk2; Xenopus;
D O I
10.1038/sj.emboj.7600328
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) and thereby promote cell cycle progression. In vertebrates, Chk1 and Chk2 phosphorylate Cdc25A at multiple N-terminal sites and target it for rapid degradation in response to genotoxic stress. Here we show that Chk1, but not Chk2, phosphorylates Xenopus Cdc25A at a novel C-terminal site (Thr504) and inhibits it from C-terminally interacting with various Cdk-cyclin complexes, including Cdk1-cyclin A, Cdk1-cyclin B, and Cdk2-cyclin E. Strikingly, this inhibition, rather than degradation itself, of Cdc25A is essential for the Chk1-induced cell cycle arrest and the DNA replication checkpoint in early embryos. 14-3-3 proteins bind to Chk1-phosphorylated Thr504, but this binding is not required for the inhibitory effect of Thr504 phosphorylation. A C-terminal site presumably equivalent to Thr504 exists in all known Cdc25 family members from yeast to humans, and its phosphorylation by Chk1 (but not Chk2) can also inhibit all examined Cdc25 family members from C-terminally interacting with their Cdk-cyclin substrates. Thus, Chk1 but not Chk2 seems to inhibit virtually all Cdc25 phosphatases by a novel common mechanism.
引用
收藏
页码:3386 / 3396
页数:11
相关论文
共 50 条
  • [41] 下调Chk1和Chk2基因促进射线照射后HeLa细胞凋亡
    高庆蕾
    叶飞
    邢辉谢
    大兴
    卢运萍
    周剑锋
    马丁
    中华肿瘤杂志, 2009, (03)
  • [42] Chk1/chk2在Aβ致伤海马神经元中的表达及意义
    黄昕艳
    尉荣翠
    杨智
    李壮
    刘爽
    黑龙江医药科学, 2015, 38 (01) : 72 - 73
  • [43] A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation
    Zhan Xiao
    John Xue
    Thomas J Sowin
    Saul H Rosenberg
    Haiying Zhang
    Oncogene, 2005, 24 : 1403 - 1411
  • [44] 人脑胶质瘤中ATM、ATR、Chk1和Chk2基因表达研究
    周雪梅
    乔健
    王娆
    黄建萍
    王慧博
    邱裕友
    陈永珍
    中华神经医学杂志, 2009, (07) : 653 - 657
  • [45] 细胞周期检测点激酶CHK1、CHK2与放射敏感性
    王玉祥
    祝淑钗
    肿瘤学杂志, 2007, (03) : 178 - 181
  • [46] In vitro and in vivo potentiation of cytotoxic therapy by XL844, an orally bioavailable inhibitor of Chk1 and Chk2
    Matthews, David J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3504S - 3505S
  • [47] Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation
    Ye, F.
    Yang, Z.
    Liu, Y.
    Gong, D.
    Ji, T.
    Wang, J.
    Xi, B.
    Zhou, J.
    Ma, D.
    Gao, Q.
    CANCER GENE THERAPY, 2014, 21 (05) : 209 - 217
  • [48] Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines
    Papp, Thilo
    Niemetz, Annett
    Dosdahl, Nils
    Kumar, Krishan
    Schiffmann, Dietmar
    ONCOLOGY REPORTS, 2007, 17 (01) : 135 - 140
  • [49] A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation
    Xiao, Z
    Xue, J
    Sowin, TJ
    Rosenberg, SH
    Zhang, HY
    ONCOGENE, 2005, 24 (08) : 1403 - 1411
  • [50] Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
    Stracker, Travis H.
    Usui, Takehiko
    Petrini, John H. J.
    DNA REPAIR, 2009, 8 (09) : 1047 - 1054